Apeximmune Therapeutics Announces Successful Close of Series A Fundraising Round to Advance Next-Generation Immunotherapies
Apeximmune Therapeutics, a biotechnology company pioneering next-generation immunotherapies, today announced the successful close of its Series A financing round, raising $21.3 million, exceeding its original goal of $20 million. The funding was led by PharmaEssentia Corporation, with participation... - April 01, 2025
Press Releases 1 - 1 of 1